Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heritability of metoprolol and torsemide pharmacokinetics.

Clinical pharmacology and therapeutics - 1 Dec 2015

Matthaei J, Brockmöller J, Tzvetkov M V, Sehrt D, Sachse-Seeboth C, Hjelmborg J B, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R

Abstract excerpt

Genetic variation in the pharmacokinetics of metoprolol and torsemide due to polymorphisms in CYP2D6, CYP2C9, and OATP1B1 has been extensively studied. However, it is still unknown how much of the variation in pharmacokinetics of these two clinically important drugs in total is due to genetic fac...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Cytochrome P-450 CYP2C9
Share to Heredity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Infusions, Intravenous

Share to Liver-Specific Organic Anion Transporter 1

Share to Metoprolol

Share to Organic Anion Transporters

Share to Twins, Dizygotic

Source

Identifiers

PMID: 26344676
DOI: 10.1002/cpt.258

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26344676-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heritability of metoprolol and torsemide pharmacokinetics.PMID 26344676Read ↗

Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters.Semantic proximity Read ↗

Inherited and Acquired Determinants of Hepatic CYP3A Activity in HumansSemantic proximity Read ↗

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.Semantic proximity Read ↗

Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.Semantic proximity Read ↗

Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins.Semantic proximity Read ↗

Genetic variation at the CYP2C locus and its association with torsemide biotransformation.Semantic proximity Read ↗

Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.Semantic proximity Read ↗

Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol TartrateSemantic proximity Read ↗

Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences.Semantic proximity Read ↗

Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.Semantic proximity Read ↗

An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia.Semantic proximity Read ↗

Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.